Page 142 - 南京医科大学自然版

第44卷第5期
·730 · 南 京 医 科 大 学 学 报 2024年5月

2022，40（11）：1186-1193 ［20］SASADA S，KIMURA Y，MASUMOTO N，et al. Breast
［8］ YUGE S，MIYAKE K K，ISHIMORI T，et al. Reproduc⁃ cancer detection by dedicated breast positron emission to⁃
ibility assessment of uptake on dedicated breast PET for mographyaccording to the World Health Organization
noisediscrimination［J］. Ann Nucl Med，2023，37（2）： classification of breast tumors［J］. Eur J Surg Oncol，
121-130 2021，47（7）：1588-1592
［9］ ITAGAKI K，MIYAKE K K，TANOUE M，et al. Feasibili⁃ ［21］MASUMOTO N，KADOYA T，SASADA S，et al. Intratu⁃
ty of dedicated breast positron emission tomography im⁃ moral heterogeneity on dedicated breast positron emission
age denoising using a residual neural network［J］. Asia tomographypredicts malignancy grade of breast cancer［J］.
Ocean J Nucl Med Biol，2023，11（2）：145-157 Breast Cancer Res Treat，2018，171（2）：315-323
［10］SASADA S，MASUMOTO N，GODA N，et al. Which type ［22］GRANA⁃LOPEZ L，HERRANZ M，DOMINGUEZ⁃PRA⁃
of breast cancers is undetectable on ring⁃type dedicated DO I，et al. Can dedicated breast PET help to reduce over⁃
breast PET?［J］. Clin Imaging，2018，51：186-191 diagnosis and overtreatment bydifferentiating between in⁃
［11］HASHIMOTO R，AKASHI⁃TANAKA S，WATANABE C， dolent and potentially aggressive ductal carcinoma insi⁃
et al. Diagnostic performance of dedicated breast positron tu?［J］. Eur Radiol，2020，30（1）：514-522
emission tomography［J］. Breast Cancer，2022，29（6）： ［23］GRANA⁃LOPEZ L，HERRANZ M，DOMINGUEZ⁃PRA⁃
1013-1021 DO I，et al. Dedicated breast PET value to evaluate BI⁃
［12］SHIMIZU Y，SATAKE H，ISHIGAKI S，et al. Physiologi⁃ RADS 4 breast lesions［J］. Eur J Radiol，2018，108：201-
cal background parenchymal uptake of（18）F ⁃ FDG in 207
normal breast tissuesusing dedicated breast PET：correla⁃ ［24］WANG H，MAO X. Evaluation of the efficacy of neoadju⁃
tion with mammographic breast composition，menopausal vant chemotherapy for breast cancer［J］. Drug Des Devel
status，and menstrual cycle［J］. Ann Nucl Med，2022，36 Ther，2020，14：2423-2433
（8）：728-735 ［25］RAUCH G M，ADRADA B E，KUERER H M，et al. Multi⁃
［13］MIYAKE K K，KATAOKA M，ISHIMORI T，et al. A pro⁃ modality imaging for evaluating responseto neoadjuvant
posed dedicated breast PET lexicon：standardization of de⁃ chemotherapy in breast cancer［J］. AJR Am J Roentgen⁃
scription and reporting of radiotracer uptake in the ol，2017，208（2）：290-299
breast［J］. Diagnostics（Basel），2021，11（7）：1267 ［26］BAUMGARTNER A，TAUSCH C，HOSCH S，et al. Ultra⁃
［14］SASADA S，MASUMOTO N，EMI A，et al. Malignant pre⁃ sound⁃based prediction of pathologic response to neoadju⁃
diction of incidental findings using ring ⁃ type dedicated vant chemotherapy inbreast cancer patients［J］. Breast，
breastpositron emission tomography［J］. Sci Rep，2022，12 2018，39：19-23
（1）：1144 ［27］ZHANG J，HUANG Y，CHEN J，et al. Potential of combi⁃
［15］SATOH Y，MOTOSUGI U，OMIYA Y，et al. Unexpected nation of DCE ⁃ MRI and DWI with serum CA125 and
abnormal uptake in the breasts at dedicated breast PET： CA199 inevaluating effectiveness of neoadjuvant chemo⁃
incidentally detected small cancers or nonmalignant fea⁃ therapy in breast cancer［J］. World J Surg Oncol，2021，19
tures?［J］. AJR Am J Roentgenol，2019，212（2）：443-449 （1）：284
［16］SAKAGUCHI R，KATAOKA M，KANAO S，et al. Distri⁃ ［28］SASADA S，MASUMOTO N，GODA N，et al. Dedicated
bution pattern of FDG uptake using ring⁃type dedicated breast PET for detecting residual disease after neoadju⁃
breast PET incomparison to whole⁃body PET/CT scanning vantchemotherapy in operable breast cancer：a prospec⁃
in invasive breast cancer［J］. Ann Nucl Med，2019，33 tive cohort study［J］. Eur J Surg Oncol，2018，44（4）：
（8）：570-578 444-448
［17］SASADA S，KAI A，KIMURA Y，et al. Four patterns of ab⁃ ［29］KOYASU H，GOSHIMA S，NODA Y，et al. The feasibility
normal ring ⁃ like uptakes on dedicated breast PET［J］. of dedicated breast PET for the assessment of residual tu⁃
Clin Nucl Med，2022，47（2）：e192-e193 morafter neoadjuvant chemotherapy［J］. Jpn J Radiol，
［18］张建兴. 多种影像学方法在中国乳腺癌筛查中的应 2019，37（1）：81-87
用［J］. 实用医学杂志，2017，33（9）：1365-1368 ［30］TOKUDA Y，YANAGAWA M，FUJITA Y，et al. Predic⁃
［19］YUGE S，MIYAKE K K，ISHIMORI T，et al. Performance tion of pathological complete response after neoadjuvant
of dedicated breast PET in breast cancer screening：com⁃ chemotherapy inbreast cancer：comparison of diagnostic
parison withdigital mammography plus digital breast tomo⁃ performances of dedicated breast PET，whole⁃body PET，
synthesis and ultrasound［J］. Ann Nucl Med，2023，37 and dynamic contrast⁃enhanced MRI［J］. Breast Cancer
（9）：479-493 Res Treat，2021，188（1）：107-115